Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04126200 · ClinicalTrials.gov registry record · Phase 2

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
208
Enrollment target
20
Study locations

NCT04126200 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 208 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04126200, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
208 participants
Enrollment target
20
Study locations

Study Summary

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Belantamab mafodotin
  • DRUG Nirogacestat
  • DRUG Dostarlimab
  • DRUG GSK3174998
  • DRUG Feladilimab

Study Locations (20)

Other

  • GSK Investigational Site - Porto Alegre
  • GSK Investigational Site - Salvador
  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - Lille
  • GSK Investigational Site - Villejuif
  • GSK Investigational Site - Frankfurt
  • GSK Investigational Site - Hamburg
  • GSK Investigational Site - Kiel
  • GSK Investigational Site - Leipzig
  • GSK Investigational Site - Athens

Victoria

  • GSK Investigational Site - Fitzroy
  • GSK Investigational Site - Melbourne

Georgia

  • GSK Investigational Site - Atlanta

Indiana

  • GSK Investigational Site - Indianapolis

Massachusetts

  • GSK Investigational Site - Boston

Michigan

  • GSK Investigational Site - Grand Rapids

Wisconsin

  • GSK Investigational Site - Madison

British Columbia

  • GSK Investigational Site - Vancouver

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2019-10-07
Est. Completion 2027-03-11
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04126200

The ClinicalTrials.gov registry entry for NCT04126200 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (62% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Belantamab mafodotin is the first listed.

NCT04126200 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Victoria, Georgia.

Frequently Asked Questions

What is clinical trial NCT04126200 about?

NCT04126200 is a clinical study titled "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)". B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study des...

What is the current status of trial NCT04126200?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2019-10-07. Estimated completion is 2027-03-11.

What conditions does trial NCT04126200 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04126200?

The interventions under investigation include: Belantamab mafodotin (DRUG), Nirogacestat (DRUG), Dostarlimab (DRUG), GSK3174998 (DRUG), Feladilimab (DRUG).

Who is sponsoring clinical trial NCT04126200?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04126200 being conducted?

This trial has 20 study locations across Georgia, Indiana, Massachusetts, Michigan, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.